MEDICLINIC INTERNATIONAL PLC Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
('Mediclinic', the 'Company'or the 'Group')
30 May 2018
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEMOn 24 and 25 May 2018, Mr Danie Meintjes, Chief Executive Officer of Mediclinic International plc, sold a total of 49 423 shares in the Company, being the shares awarded to Mr Meintjes in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017. Mr Meintjes retained the totality of the shares at the time but has now disposed of them to cover personal tax liabilities. Mr Meintjes continues to hold 123900shares in the Company.
The notification below is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.
1. | Details of PDMR / person closely associated with them ('PCA') | |||||
a) | Name | Mr Daniël Petrus Meintjes | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Executive Officer of the Company | ||||
b) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mediclinic International plc | ||||
b) | LEI | 2138002S5BSBIZTD5I60 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Sale of shares awarded in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017 | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 17 423 ZAR 110.01 | ||||
e) | Date of the transaction | 24 May 2018 | ||||
f) | Place of the transaction | Johannesburg Stock Exchange | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification Code | Ordinary Shares GB00B8HX8Z88 | ||||
b) | Nature of the transaction | Sale of sharesawarded in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017 | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | 32 000 ZAR 107.01 | ||||
e) | Date of the transaction | 25 May 2018 | ||||
f) | Place of the transaction | Johannesburg Stock Exchange | ||||
About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.
Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Attachments
- Original document
- Permalink
Disclaimer
Mediclinic International plc published this content on 30 May 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 May 2018 14:07:05 UTC
